



**I-MAB**  
BIOPHARMA

## I-Mab Announces Participation at Jefferies and Piper Conferences in November

November 6, 2023

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35<sup>th</sup> Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

### Jefferies London Healthcare Conference (In Person)

Presentation Time	Tuesday, November 14 <sup>th</sup> at 10:30 a.m. GMT (5:30 a.m. EST)
Presenters	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO
Webcast link	<a href="https://wsw.com/webcast/jeff287/imab/1828028">https://wsw.com/webcast/jeff287/imab/1828028</a> The webcast will also be available under "Event Calendar" on I-Mab's IR website at <a href="http://ir.i-mabbiopharma.com/">http://ir.i-mabbiopharma.com/</a>
Meetings	One-on-one and small group meetings: Nov 14 – 16, 2023
Management Participants	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Jefferies representative.

### Piper Sandler 35<sup>th</sup> Annual Healthcare Conference (In Person)

Presentation Time	Thursday, November 30 <sup>th</sup> at 8:30 a.m. EST
Presenters	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO
Meetings	One-on-one and small group meetings: Nov 28 – 30, 2023
Management Participants	Mr. Raj Kannan, CEO Dr. John Hayslip, CMO Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Piper Sandler representative.

### About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit <https://www.i-mabbiopharma.com> and follow us on [LinkedIn](#), [X, formerly known as Twitter](#), and [WeChat](#).

### I-Mab Contacts

<b>Investors</b>	<b>Media</b>
Tyler Ehler	Gigi Feng
Senior Director, Investor Relations	Chief Communications Officer
<a href="mailto:IR@i-mabbiopharma.com">IR@i-mabbiopharma.com</a>	<a href="mailto:PR@i-mabbiopharma.com">PR@i-mabbiopharma.com</a>

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/i-mab-announces-participation-at-jefferies-and-piper-conferences-in-november-301978319.html>

SOURCE I-Mab